Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar Survival Outcomes as Compared to Upfront Percutaneous Ablation Allowing for Follow-Up Treatment in Those with Single Hepatocellular Carcinoma (HCC) ≤ 3 cm: Results of a Real-World Propensity-Matched Multi-Centre Australian Cohort Study

• Published in: Cancers Vol. 16; no. 17; p. 3010
• Main Authors: Abdelmalak, Jonathan, Strasser, Simone I, Ngu, Natalie L, Dennis, Claude, Sinclair, Marie, Majumdar, Avik, Collins, Kate, Bateman, Katherine, Dev, Anouk, Abasszade, Joshua H, Valaydon, Zina, Saitta, Daniel, Gazelakis, Kathryn, Byers, Susan, Holmes, Jacinta, Thompson, Alexander J, Howell, Jessica, Pandiaraja, Dhivya, Bollipo, Steven, Sharma, Suresh, Joseph, Merlyn, Sawhney, Rohit, Nicoll, Amanda, Batt, Nicholas, Tang, Myo J, Riordan, Stephen, Hannah, Nicholas, Haridy, James, Sood, Siddharth, Lam, Eileen, Greenhill, Elysia, Lubel, John, Kemp, William, Majeed, Ammar, Zalcberg, John, Roberts, Stuart K
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 29-08-2024
• Subjects: Ablation; Cancer therapies; Cohort analysis; Diabetes; Embolization; Hepatocellular carcinoma; Liver cancer; Liver diseases; Liver transplantation; Liver transplants; Medical prognosis; Medical records; Mortality; Patients; Regression analysis; Software; Statistical significance; Survival; Survival analysis; United States > US; single; small; TACE; early; hepatocellular carcinoma; ablation
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16173010

Percutaneous ablation is recommended in Barcelona Clinic Liver Cancer (BCLC) stage 0/A patients with HCC ≤3 cm as a curative treatment modality alongside surgical resection and liver transplantation. However, trans-arterial chemo-embolisation (TACE) is commonly used in the real-world as an initial treatment in patients with single small HCC in contrast to widely accepted clinical practice guidelines which typically describe TACE as a treatment for intermediate-stage HCC. We performed this real-world propensity-matched multi-centre cohort study in patients with single HCC ≤ 3 cm to assess for differences in survival outcomes between those undergoing initial TACE and those receiving upfront ablation. Patients with a new diagnosis of BCLC 0/A HCC with a single tumour ≤3 cm first diagnosed between 1 January 2016 and 31 December 2020 who received initial TACE or ablation were included in the study. A total of 348 patients were included in the study, with 147 patients receiving initial TACE and 201 patients undergoing upfront ablation. After propensity score matching using key covariates, 230 patients were available for analysis with 115 in each group. There were no significant differences in overall survival (log-rank test
= 0.652) or liver-related survival (log-rank test
= 0.495) over a median follow-up of 43 months. While rates of CR were superior after ablation compared to TACE as a first treatment (74% vs. 56%,
< 0.004), there was no significant difference in CR rates when allowing for further subsequent treatments (86% vs. 80%
= 0.219). In those who achieved CR, recurrence-free survival and local recurrence-free survival were similar (log rank test
= 0.355 and
= 0.390, respectively). Our study provides valuable real-world evidence that TACE when offered with appropriate follow-up treatment is a reasonable initial management strategy in very early/early-stage HCC, with similar survival outcomes as compared to those managed with upfront ablation. Further work is needed to better define the role for TACE in BCLC 0/A HCC.